temozolomide
Showing 1 - 25 of 556
Pheochromocytoma, Paraganglioma Trial in Beijing (Temozolomide)
Recruiting
- Pheochromocytoma
- Paraganglioma
- Temozolomide
-
Beijing, ChinaPeking Union Medical College Hospital
May 22, 2023
Recurrent Glioblastoma Trial in Beijing (Laser interstitial thermal therapy, Temozolomide)
Active, not recruiting
- Recurrent Glioblastoma
- Laser interstitial thermal therapy
- Temozolomide
-
Beijing, ChinaBeijing Tiantan Hospital
Dec 22, 2022
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma Trial in Padova (Regorafenib, Temozolomide)
Recruiting
- Glioblastoma, IDH-wildtype
- MGMT-Methylated Glioblastoma
- Regorafenib
- Temozolomide
-
Padova, ItalyIstituto Oncologico Veneto IRCCS
Oct 18, 2023
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III Trial in San Antonio, Zuerich (Debio 0123,
Not yet recruiting
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Astrocytoma, Grade III
- Debio 0123
- +2 more
-
San Antonio, Texas
- +1 more
Mar 9, 2023
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme Trial in Cleveland (Eflornithine (Dose Level 1), Eflornithine
Recruiting
- Glioblastoma, IDH-wildtype
- +4 more
- Eflornithine (Dose Level 1)
- +3 more
-
Cleveland, OhioThe Cleveland Clinic
May 19, 2023
Ewing Sarcoma Trial in Beijing (Vincristine, Temozolomide)
Recruiting
- Ewing Sarcoma
- Vincristine
- Temozolomide
-
Beijing, Beijing, ChinaPeking University People's Hospital
Oct 31, 2022
Glioblastoma Multiforme Trial in Seoul (BEY1107, Temozolomide)
Recruiting
- Glioblastoma Multiforme
- BEY1107
- Temozolomide
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 13, 2023
Recurrent Extensive Stage Small Cell Lung Carcinoma Trial in Hangzhou, Nanjing, Zhengzhou (HTMC0435, Temozolomide)
Not yet recruiting
- Recurrent Extensive Stage Small Cell Lung Carcinoma
- HTMC0435
- Temozolomide
-
Hangzhou, China
- +2 more
Feb 5, 2023
Glioblastoma Multiforme (GBM) Trial in Taoyuan (ADI-PEG20, Temozolomide)
Recruiting
- Glioblastoma Multiforme (GBM)
- ADI-PEG20
- Temozolomide
-
Taoyuan, TaiwanChang Gung Memorial Hospital, Linkou Branch
Sep 29, 2022
Glioblastoma Trial run by the NCI (drug, biological, other)
Completed
- Glioblastoma
- Pembrolizumab
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 23, 2022
Glioblastoma Multiforme Trial in Baltimore (Retifanlimab, Temozolomide, Radiation Therapy)
Recruiting
- Glioblastoma Multiforme
- Retifanlimab
- +2 more
-
Baltimore, MarylandJohns Hopkins Medical Institution
Dec 5, 2022
Recurrent Pituitary Adenomas Trial in New York (Capecitabine, Temozolomide)
Terminated
- Recurrent Pituitary Adenomas
- Capecitabine
- Temozolomide
-
New York, New YorkWeill Cornell Medical College
Jul 15, 2022
Anaplastic Oligoastrocytoma, Glioblastoma Trial in Guangzhou (Temozolomide)
Recruiting
- Anaplastic Oligoastrocytoma
- Glioblastoma
- Temozolomide
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 27, 2022
Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma Trial (PCI 24781, Temozolomide)
Not yet recruiting
- Recurrent High Grade Glioma
- +4 more
- PCI 24781
- Temozolomide
- (no location specified)
Jan 24, 2023
Relapsed Neuroblastoma, Refractory Neuroblastoma Trial (Natural Killer Cells, Temozolomide, Irinotecan)
Recruiting
- Relapsed Neuroblastoma
- Refractory Neuroblastoma
- Natural Killer Cells
- +4 more
-
Columbus, OhioNationwide Children's Hospital
Oct 26, 2022
Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)
Active, not recruiting
- Breast Cancer
- +3 more
- ABT-888
- temozolomide
-
Boston, Massachusetts
- +2 more
Dec 21, 2022
Glioblastoma Trial (Hypofractionated radiotherapy, Conventional radiotherapy, Temozolomide)
Not yet recruiting
- Glioblastoma
- Hypofractionated radiotherapy
- +2 more
- (no location specified)
Jun 27, 2022
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 Trial in New York
Recruiting
- Locally Advanced Leiomyosarcoma
- +5 more
- Olaparib
- +3 more
-
New York, New YorkColumbia University/Herbert Irving Cancer Center
Jan 4, 2023
Melanoma (Skin) Trial in Philadelphia (sorafenib tosylate, temozolomide)
Completed
- Melanoma (Skin)
- sorafenib tosylate
- temozolomide
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jun 13, 2022
Malignant Glioma, Glioblastoma, Gliosarcoma Trial in Durham (Bevacizumab, Temozolomide, Radiation Therapy (XRT))
Completed
- Malignant Glioma
- +2 more
- Bevacizumab
- +3 more
-
Durham, North CarolinaThe Preston Robert Tisch Brain Tumor Center at Duke
Mar 29, 2022
Glioblastoma Trial in Oklahoma City (OKN 007, Temozolomide, Photon/Proton IMRT)
Recruiting
- Glioblastoma
- OKN 007
- +2 more
-
Oklahoma City, OklahomaStephenson Cancer Center, University of Oklahoma Health Sciences
Jun 17, 2022
Platinum-Sensitive Biliary Tract Cancer Trial (Cisplatin, Gemcitabine, Oxaliplatin)
Withdrawn
- Platinum-Sensitive Biliary Tract Cancer
- Cisplatin
- +4 more
- (no location specified)
May 27, 2022
Sarcoma, Ewing, Rhabdomyosarcoma Trial run by the National Cancer Institute (NCI) (PEN-866, Vincristine, Temozolomide)
Not yet recruiting
- Sarcoma, Ewing
- Rhabdomyosarcoma
- PEN-866
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Glioblastoma Multiforme Trial in Saint Louis (drug, procedure, radiation)
Active, not recruiting
- Glioblastoma Multiforme
- Disulfiram
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 22, 2022
Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphoid System Tumor, Malignant Solid Tumor Trial run by the National Cancer
Recruiting
- Adrenal Gland Pheochromocytoma
- +3 more
- Computed Tomography
- +2 more
-
Bethesda, Maryland
- +1 more
Jan 3, 2023